Abstract Abstract 4429 Background Imatinib mesylate (IM) is considered the mainstay of
chronic myeloid leukemia (CML) treatment for almost a decade. The primary goal of the …

Purpose There is a considerable variability in the level of molecular responses achieved
with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences …

Chronic myelogeneous leukemia (CML) is characterised by a specific translocation t (9;
22)(q34; q11), the Philadelphia (Ph) chromosome, giving rise to the novel BCR/ABL fusion …

Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive
imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL …

A leucemia mieloide crônica (LMC) é uma doença mieloproliferativa clonal caracterizada
citogeneticamente pelo cromossomo Philadelphia. Dentre as opções terapêuticas estão a …

Purpose: The purpose of our investigation was to evaluate the response and minimal
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …

Sustained imatinib treatment in chronic myeloid leukemia patients can result in complete
molecular response allowing discontinuation without relapse. We set out to evaluate the …

Background: Imatinib resistance (IR) is a well known cause of treatment failure in chronic
myeloid leukemia (CML) patients being treated with imatinib mesylate (IM). Several cellular …

Correlation between trough imatinib plasma concentration and clinical response in chronic
myeloid leukemia. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe …

The use of the tyrosine kinase inhibitor imatinib, which blocks the enzymatic action of the
BCR–ABL fusion protein, has represented a critical advance in chronic myeloid leukemia …